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Abstract 1 
Objective Until now, long-term outcome studies have focused on general cognitive functioning and its 2 
risk factors following neonatal extracorporeal membrane oxygenation (ECMO) and/or congenital 3 
diaphragmatic hernia (CDH). However, it is currently unknown which neuropsychological domains are 4 
most affected in these patients, and which clinical variables can be used to predict specific 5 
neuropsychological problems. This study aimed to identify affected neuropsychological domains and its 6 
clinical determinants in survivors of neonatal ECMO and/or CDH.   7 
Design Prospective follow-up study. 8 
Setting Tertiary university hospital. 9 
Patients Sixty-five eight-year-old survivors of neonatal ECMO and/or CDH.  10 
Interventions None. 11 
Measurements and Main Results Intelligence, attention, memory, executive functioning and 12 
visuospatial processing were evaluated using validated tests and compared with Dutch reference data. 13 
Assessed risk factors of outcome were illness severity indicators, number of anesthetic procedures in the 14 
first year of life and growth at one year.  15 
Patients had average intelligence (mean IQ±SD:95±16), but significantly poorer sustained attention (mean 16 
z-score±SD:─2.73±2.57), verbal (immediate:─1.09±1.27;delayed:─1.14±1.86) and visuospatial memory 17 
(immediate: ─1.48±1.02;delayed: ─1.57±1.01;recognition:─1.07±3.10) than the norm. ECMO-treated 18 
CDH patients had significantly lower mean IQ (84±12) than other neonatal ECMO patients (94±10) and 19 
CDH patients not treated with ECMO (100±20). Maximum vasoactive-inotropic score was negatively 20 
associated with delayed verbal (B=─0.02, 95%CI:─0.03 to ─0.002, p=.026) and visuospatial memory 21 
(B=─0.01, 95%CI:─0.02 to ─0.001, p=.024). 22 
Conclusions We found memory and attention deficits in eight-year-old neonatal ECMO and CDH 23 
survivors. The maximum dose of vasoactive medication was negatively associated with verbal and 24 
visuospatial memory, which may suggest an effect of early cerebral hypoperfusion in determining these 25 
abnormalities.  26 
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Introduction 1 
The majority of children growing up following neonatal extracorporeal membrane oxygenation (ECMO) 2 
and/or congenital diaphragmatic hernia (CDH) have a generally average IQ, yet show impaired 3 
neurodevelopmental outcome and school problems.(1-3) Until now, most long-term studies of school-age 4 
survivors have focused on IQ and attention, hampering our understanding of the specific 5 
neuropsychological problems after neonatal critical illness.(1-3) Furthermore, it remains largely unclear 6 
which patients are at risk of impaired outcome and why. For early identification and intervention of 7 
patients at risk, it is crucial to increase our understanding of neuropsychological domains most frequently 8 
impaired and the risk factors determining impaired outcome.  9 
Earlier studies have found that markers of illness severity, such as ECMO requirement and the 10 
presence of chronic lung disease, were predictive of neuropsychological deficits in CDH patients.(2) Still, 11 
clinically useful risk factors of such deficits following neonatal critical illness remain unknown. Our 12 
group has recently shown specific hippocampal volume alterations that were related to verbal memory 13 
impairments in school-aged neonatal ECMO survivors.(4,5) The hippocampus appears specifically 14 
vulnerable to hypoxic-ischemic injuries.(6,7) Using measures of hypoperfusion could possibly aid in 15 
predicting neuropsychological outcomes following neonatal critical illness, as hypoperfusion may result 16 
in hypoxic-ischemic and eventually reperfusion injury in the hippocampus. Additionally, poor growth in 17 
the first year of life has been reported in CDH and ECMO-treated patients(8,9) and has been associated 18 
with worse neurodevelopmental outcome.(10,11) However, the effects of poor growth on specific 19 
neuropsychological functions in school-aged survivors of neonatal critical illness remain unknown. 20 
In this study, neuropsychological outcome was evaluated in school-aged CDH survivors treated 21 
with or without neonatal ECMO and in neonatal ECMO-treated survivors following other diagnoses. We 22 
hypothesized that children would mainly have attention and memory deficits, despite a generally average 23 
IQ. We expected markers of increased severity of illness and hypoperfusion as well as poor growth in the 24 
first year of life to have negatively affected neuropsychological outcome at school-age.  25 
 26 
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Material and Methods 1 
Population  2 
We included CDH and neonatal ECMO patients born between January 2006 and March 2009. 3 
Participants were routinely seen at eight years as part of a structured prospective longitudinal follow-up 4 
program that includes regular physical and neurodevelopmental assessments until 18 years.(12) ECMO 5 
treatment was applied in case of severe respiratory failure using the criteria described by Stolar et al.(13). 6 
Since November 2007, CDH patients were treated according to the standardized CDH-EURO Consortium 7 
treatment protocol.(14) In case of persistent poor tissue perfusion and/or hypotension (arterial blood 8 
pressure below normal levels for gestational age and not improving after fluid boluses), treatment with 9 
dobutamine and/ordopamine was initiated, followed by norepinephrine, epinephrine or milrinone in case 10 
of persistent hypotension. Exclusion criteria were: genetic syndromes known to affect neurodevelopment, 11 
severe neurologic or developmental impairments preventing standardized assessments, late CDH 12 
diagnosis(>7 days of life), or a paraesophageal hernia. We used a protocol with extended 13 
neuropsychological assessments, implemented in January 2014 (Supplemental File 1).(1,2) Included 14 
children were divided into three groups: ECMO patients following other diagnoses than CDH(“ECMO-15 
other”), CDH patients treated with ECMO(“CDH-ECMO”) and CDH patients not treated with 16 
ECMO(“CDH-non-ECMO”). This post-ECMO/CDH follow-up program is standard of care, therefore 17 
Institutional Review Board approval was waived(MEC-2017-185).(2,15) 18 
 19 
Data collection  20 
Relevant clinical data were collected at the time of hospitalization (Supplemental Methods). The Pediatric 21 
Logistic Organ Dysfunction-2(PELOD-2) score(16) was collected in the first 24 hours of pediatric 22 
intensive care unit(PICU) stay (or up to ECMO cannulation in ECMO-treated patients if ECMO was 23 
initiated within the first 24 hours of PICU stay), the maximum vasoactive-inotropic score(VIS)(17) was 24 
recorded up until ECMO cannulation for the ECMO-treated patients or up until hernia repair for the 25 
CDH-non-ECMO patients.  26 
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Follow-up data included growth measurements (height, weight, head circumference) at 6 months 1 
and 1 year, which were converted into z-scores (individual score minus the norm score divided by the 2 
norm SD).(19) Height-corrected-for-target height z-score was calculated as follows: height-for-age z-3 
score–target height z-score.(20)  4 
Neuropsychological evaluation was performed by an experienced pediatric psychologist. 5 
Socioeconomic status was assessed from maternal education level.(21)  6 
 7 
Neurodevelopmental outcome tests 8 
Validated neuropsychological tests were administered in their Dutch versions to assess skills in six 9 
domains (Supplemental File 1):  10 
1 IQ: Two-subtest short-form(Block Design and Vocabulary) of the Wechsler Intelligence 11 
Scale for Children(WISC-III-NL)(22). 12 
2 Attention:  13 
a. Processing speed: Trail Making Test section A(TMTA)(23,24). 14 
b. Selective attention and cognitive flexibility: STROOP color-word test(stroop)(23,24) and 15 
Trail Making Test section B(TMTB)(23,24). 16 
c. Sustained attention: Dot Cancellation Test(DCT)(25). 17 
3 Verbal memory:  18 
a. Working-memory: subtest Digit Span of the WISC-III-NL(22).  19 
b. Immediate and delayed recall: Rey Auditory Verbal Learning Test(RAVLT)(26). 20 
4 Visuospatial memory:  21 
a. Working-memory: subtest Spatial Span of the Wechsler Nonverbal Scale of 22 
Ability(WNV)(27).  23 
b. Immediate and delayed recall: Rey Complex Figure Test(RCFT)(28). 24 
5 Executive functioning: Key Search and Modified Six Elements of the Behavioral Assessment 25 
of the Dysexecutive Syndrome(BADS-C-NL)(29).   26 
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6 Visuospatial processing: Copy of the Rey Complex Figure Test(RCFT Copy)(28).  1 
Neuropsychological test scores were converted into z-scores. Scores were inverted where appropriate so 2 
that a higher score always equated with better performance. Z-scores≤ -1 were regarded as likely to 3 
represent impaired functioning (general population:mean z-score=0; SD=1)(23).  4 
 5 
Statistical analysis  6 
Differences in patient characteristics between the three groups(ECMO-other, CDH-ECMO and CDH-7 
non-ECMO) were evaluated with chi-square or Fisher’s exact tests for categorical variables, and with 8 
independent samples t-tests and one-way analysis of variance(ANOVA) for normally distributed 9 
variables. Mann-Whitney U tests and Kruskal-Wallis tests were used for continuous variables that were 10 
not normally distributed. Differences in neuropsychological outcome between the three groups were 11 
assessed with one-way ANOVA. 12 
Univariable analyses were performed to assess the influence of clinical characteristics on the 13 
following neuropsychological outcomes of interest: intelligence, sustained attention, verbal memory 14 
immediate recall, verbal memory delayed recall, visuospatial memory immediate recall and visuospatial 15 
memory delayed recall. The independent variables included: maximum VIS, ECMO, type of 16 
ECMO(venoarterial or venovenous), sepsis, ventilator-free days in the first 28 days of life, duration of 17 
initial hospital stay, growth z-scores at 1 year (paired t-test showed largest growth deflection from 6 18 
months to 1 year) and number of anesthetic procedures during the first year of life.Next, multivariable 19 
linear regression analyses were used to identify which independent variables remained significant 20 
predictors in a multivariable model. The assumptions for linear regression analysis were checked with 21 
normal probability plots of the residuals. Multicollinearity was evaluated in the multivariable models 22 
using the criterion that variance inflation factors should not exceed 2.5(30). 23 
Analyses were performed with SPSS 21.0(IBM, Armonk, NY, USA), a two-sided p-value<.05 was 24 
considered statistically significant. 25 
 26 
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Results  1 
Patient characteristics  2 
Sixty-five patients aged 8.0±0.6 years were included: 25 ECMO-other patients, 10 CDH-ECMO patients, 3 
and 30 CDH-non-ECMO patients(Supplemental Figure 1). Illness severity during hospital admission 4 
differed between the three groups(Table 1). The CDH-ECMO patients had the highest PELOD-2 score, 5 
the highest maximum VIS, the highest rate of sepsis, and the longest duration of mechanical ventilation 6 
and hospital stay. Sepsis occurred in three ECMO-other patients (during ECMO:n=2; after ECMO:n=1), 7 
four CDH-ECMO patients (after ECMO:n=4), and one CDH-non-ECMO patient after hernia repair. Four 8 
(50%) patients required vasoactive medication during sepsis. The median maximum VIS during sepsis 9 
was lower than the median maximum VIS before the ECMO run and none of the patients had a higher 10 
maximum VIS during sepsis(Table 1). Characteristics of eligible patients who were lost to follow-up or 11 
refused follow-up (n=14) did not differ from included patients(data not shown). None of the patients 12 
treated with ECMO (both ECMO-other and CDH-ECMO) had signs of cerebral hemorrhage or vessel 13 
occlusion on cranial ultrasounds performed before and after the ECMO run.  14 
 15 
Neuropsychological outcome  16 
IQ fell within the normal range for the group as a whole. Sustained attention, verbal memory (immediate 17 
and delayed recall) and visuospatial memory (immediate and delayed recall as well as recognition) were 18 
below average compared to the general population(Table 2). The majority of patients had normal 19 
outcomes in working-memory, executive functioning and visuospatial processing. However, over 50% 20 
had impaired outcomes (z-score≤-1) on one or more of the memory and attention tests(Figure 1).  21 
 When analyzing the three groups separately, we found that CDH survivors treated with ECMO 22 
had a significantly lower IQ compared to both other groups. However, no significant differences were 23 
found between the three groups on any of the other neuropsychological outcomes(Table 2). 24 
 25 
 26 
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Predictors of neuropsychological outcome  1 
Table 3 shows the results of the regression analyses. In the univariable analyses, severity of illness 2 
indicated by the need for ECMO, treatment with venoarterial-ECMO, maximum VIS, ventilator-free 3 
days, and duration of initial hospital stay were associated with neuropsychological outcome, in particular 4 
with IQ. The number of anesthetic procedures during the first year of life was associated with IQ and 5 
sustained attention, and weight-for-height at 1 year was positively associated with IQ.  6 
In the multivariable analyses, a higher maximum VIS remained associated with worse verbal and 7 
visuospatial memory delayed recall, such that an increase in maximum VIS of 20 points would result in a 8 
decrease of the verbal and visuospatial memory delayed recall z-scores of 0.4 and 0.2, respectively. 9 
Patients with impaired verbal memory had a significantly higher maximum VIS(72±44) than patients with 10 
normal verbal memory (40±32),p=.003. Patients with impaired visuospatial memory had a higher 11 
maximum VIS (64±45) than patients with normal visuospatial memory(44±33), although this was not 12 
significant(p=.118). The VIS remained a significant predictor of verbal and visuospatial memory delayed 13 
recall when group (ECMO-other, CDH-ECMO, CDH-non-ECMO) was added to the model (data not 14 
shown). 15 
Growth or other illness severity indicators were no longer associated with neuropsychological 16 
outcome in the multivariable analyses(Supplemental Table 1). 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
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Discussion 1 
This is the first study evaluating all major neuropsychological domains in school-aged survivors of 2 
neonatal ECMO and/or CDH. We found sustained attention and verbal and visuospatial memory deficits 3 
in over half of the patients, while other neuropsychological domains fell within the average range. CDH 4 
survivors treated with ECMO had lower IQ than the other two groups, who had an average IQ. 5 
Nonetheless, the observed attention and memory problems were more severe than expected based on their 6 
IQ. This incongruity between attention and memory problems with IQ for all three groups indicates 7 
specific impairments in these domains. A higher dose of vasoactive medication (indicated by the 8 
maximum VIS recorded up until ECMO cannulation or hernia repair) was associated with lower scores on 9 
verbal and visuospatial memory delayed recall. Interestingly, impaired memory and attention were found 10 
in all diagnostic groups, except for better, although not significantly, verbal memory in the CDH-non-11 
ECMO group (within one standard deviation of the norm). Attention deficits have been reported in these 12 
patients previously, also despite generally average IQ.(1-3,15) However, other neuropsychological 13 
domains were not assessed in these studies. In the present study, we evaluated all major 14 
neuropsychological domains, and thereby identified a specific neuropsychological profile following 15 
ECMO and/or CDH. Our findings may serve as a starting point for intervention-based studies designed to 16 
improve cognitive functioning in these children. 17 
As we found memory and attention deficits in the majority of patients, it is imperative to identify 18 
potential risk factors. Over the years, several severity of illness scoring systems have been developed 19 
including the VIS.(17) In the univariable analyses, maximum VIS as well as ventilator-free days and 20 
duration of initial hospital stay were independently associated with neuropsychological outcome, mainly 21 
with IQ. This indicates that severity of illness plays an important role in determining cognitive outcome in 22 
these survivors. Interestingly, in the multivariable analyses, only the maximum VIS recorded up until 23 
ECMO cannulation or hernia repair remained associated with delayed verbal and visuospatial memory. 24 
The hippocampus is highly involved in delayed memory and has previously been shown to be altered 25 
following ECMO and/or CDH.(4,5,31,32) The hippocampus has been found to be particularly susceptible 26 
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to cerebral hypoperfusion resulting in hypoxia-ischemia.(6,7,33) Although this study does not show a 1 
causative effect of vasoactive medication regarding memory problems, we speculate that receiving high 2 
levels of vasoactive medication in the first period of life may be an indirect marker of temporarily 3 
(regional) inadequate brain perfusion. A high need for vasoactive medication could therefore be a useful 4 
component in estimating severity of illness and risk of memory impairments at school-age in these 5 
survivors. Although we cannot make any recommendations based on our findings, the VIS may be 6 
valuable in determining the need for and timing of ECMO treatment in neonates with severe respiratory 7 
failure, which should be investigated in future studies. As the VIS has been validated to predict clinical 8 
outcomes in infants who require cardiac surgery(17,34), representing another group of critically ill 9 
children requiring circulatory support by vasopressor drugs. Future studies are needed to further validate 10 
the usefulness of this score for long-term outcome in neonatal critical illness survivors, and to study the 11 
direct association between maximum VIS and brain areas susceptible to ischemic-reperfusion injury such 12 
as the hippocampus. 13 
Attention and memory problems at school-age have also been found in other groups of critically 14 
ill neonates such as premature infants and infants with congenital heart disease.(31, 35) Studies in 15 
premature infants have found that lower scores on executive functioning were associated with the severity 16 
of illness(36), although others have not confirmed this(37). Multicenter studies are needed to develop a 17 
multimodal prediction model which may be the key to earlier identification of critical illness survivors at 18 
risk of impaired neurodevelopmental outcome. Predictors of interest would be specific markers of illness 19 
severity, such as the maximum VIS, in combination with predetermined assessment of neurobiological 20 
correlates, such as imaging of the hippocampus. 21 
We did not find any associations between growth at one year and long-term neuropsychological 22 
outcome. Although many CDH patients show poor growth during the first year of life(9), only one study 23 
has found an association between weight and head circumference at 2-3 years and general cognitive 24 
functioning, although not at five years.(11) In premature infants, several studies have demonstrated a 25 
positive association between weight gain and head growth and cognitive outcomes.(10) However, a recent 26 
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study in children with extremely low birth weight showed no effect of catch-up-growth in the first two 1 
years of life on neurocognitive outcome at 11 years.(38) Most studies in premature infants did not take 2 
into account the difference in severity of illness. It is therefore uncertain whether poor growth itself or 3 
severity of critical illness leading to poor growth, is more important in determining adverse 4 
neuropsychological outcome in premature infants. Although we cannot draw definitive conclusions, our 5 
study indicates that in ECMO and CDH patients, the severity of illness has a greater impact on 6 
neuropsychological outcome than growth in the first year of life. 7 
Our study has some limitations. First, the relatively small sample sizes of the three diagnostic 8 
groups is a frequent problem in follow-up studies including patients with rare diagnoses limiting the 9 
interpretability of our regression analyses. Multicenter collaborations with standardized management and 10 
structured follow-up are important to increase sample sizes and get a better understanding of the 11 
pathophysiology underlying long-term outcome. Second, MRI data were not available and we therefore 12 
could not examine whether maximum VIS was associated with brain structures susceptible to cerebral 13 
hypoperfusion. Standardized neuroimaging studies both at neonatal and school-age will aid in 14 
understanding pathophysiologic concepts of early brain development and long-term outcome, and are 15 
therefore important in future studies. Third, there are likely multiple factors involved in the development 16 
of long-term neuropsychological impairments following ECMO and/or CDH, such as exposure to 17 
inflammation(7), anesthetics(39), and stress(40) in early life, and/or a complex interplay amongst these 18 
factors. As of now, techniques to reliably measure these mechanisms and their interactions are lacking. 19 
Future studies are needed to develop specific brain monitoring techniques that can be used during PICU 20 
stay for early identification of patients at risk of long-term impairments.  21 
 22 
 23 
 24 
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Conclusions 1 
We found sustained attention, verbal and visuospatial memory deficits in eight-year-old survivors of 2 
neonatal ECMO and/or CDH. These findings emphasize the need for standardized neuropsychological 3 
follow-up including attention and memory assessments until school-age and beyond in these survivors. 4 
Maximum VIS in the first day(s) of PICU admission was negatively associated with verbal and 5 
visuospatial memory at eight years. This suggests that this measure of severity of illness, possibly 6 
indicating (cerebral) hypoperfusion during early life, is related to specific neuropsychological functions in 7 
eight year-old neonatal ECMO and/or CDH survivors. Future studies using advanced neuroimaging 8 
techniques in combination with clinical characteristics and neuropsychological evaluation will aid in a 9 
better understanding of this finding and are needed for early identification and intervention of patients at 10 
risk. Our findings of specific attention and memory problems can serve as a starting point for developing 11 
and implementing early intervention strategies that focus on improving attention and memory in these 12 
patients. 13 
 14 
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Tables  1 
Table 1. Patient characteristics 
Characteristics ECMO-other1 
(n = 25) 
CDH-ECMO 
(n = 10) 
CDH-non-ECMO 
(n = 30) 
p-value 
Gestational age (weeks) 40.9 (40.0-41.1) 39.2 (36.7-40.7) 38.5 (38.0-39.3) <0.001 
Birth weight (kilograms) 3.5 (0.5) 3.1 (0.8) 2.9 (0.4) 0.001 
Male 14 (56%) 5 (50%) 18 (60%) 0.84† 
Ethnicity 
  Dutch 
  Other 
 
19 (76%) 
6 (24%) 
 
9 (90%) 
1 (10%) 
 
26 (87%) 
4 (13%) 
0.60† 
Maternal Education Level 
           Low 
           Moderate 
           High 
           Unknown 
 
6 (24%) 
12 (48%) 
7 (28%) 
0 
 
3 (33%) 
3 (33%) 
3 (33%) 
1 
 
8 (29%) 
16 (57%) 
4 (14%) 
2 
0.592 
Inborn 4 (16%) 4 (40%) 18 (60%) 0.0032 
     
ECMO-related      
Highest oxygenation index prior 
to ECMO 
33 (28-40) 38 (26-54)  0.72 
Age start ECMO (days) 2 (1-4) 1 (1-2)  0.30 
Duration of ECMO (hours) 92 (54-100) 172 (131-212)  <0.001 
ECMO mode 
 VA 
 VV converted to VA 
 VV 
 
7 (28%) 
1 (4%) 
17 (68%) 
 
10 (100%) 
 <0.0012 
     
CDH-related     
Left sided hernia  8 (80%) 25 (83%) 1.002 
Age at surgery (days)  4 (3-6) 3 (2-4) 0.32 
Patch repair  9 (90%) 17 (57%) 0.072 
Surgical technique 
 Laparotomy 
 
 
 
10 (100%) 
 
20 (67%) 
 
0.042 
 Thoracoscopy     10 (33%)  
     
Hospital Admission-related     
PELOD-2 score3  7 (7-9) 9 (8-9) 6 (5-7) <0.001 
Maximum VIS4 
 Dobutamine treatment 
 Dopamine treatment 
 Norepinephrine treatment 
 Epinephrine treatment 
 Milrinone treatment 
 Vasopressin treatment 
40 (35-70) 
24 (96%) 
22 (88%) 
13 (52%) 
2 (8%) 
- 
- 
107 (91-142) 
10 (100%) 
7 (70%) 
10 (100%) 
- 
2 (20%) 
- 
40 (5-76) 
19 (63%) 
13 (43%) 
15 (50%) 
2 (7%) 
- 
- 
<0.001 
0.042 
0.012 
0.022 
1.002 
0.032 
- 
CPR during initial hospital stay 2 (8%) 1 (10%) 0 (0%) 0.182 
Sepsis during initial hospital 
stay5 
3 (12%) 4 (40%) 1 (3%) 0.012 
     
Days of mechanical ventilation  10 (7-11) 40 (16-51) 10 (5-18) 0.001 
20 
 
Ventilator-free days in the first 
28 days of life 
18 (17-21) 0 (0-12) 19 (10-23) 0.001 
Days of initial PICU stay 13 (10-16) 70 (24-101) 21 (12-35) <0.001 
Days of initial hospital stay  24 (21-29) 91 (48-156) 36 (20-53) 0.004 
Pulmonary hypertension 
 Yes 
 No 
 Missing 
 
13 (57%) 
10 (43%) 
2 
 
8 (80%) 
2 (20%) 
0 
 
12 (48%) 
13 (52%) 
5 
 
0.252 
Inhaled nitric oxide treatment 22 (88%) 10 (100%) 10 (33%) <0.0012 
Sildenafil treatment 2 (8%) 6 (60%)  1 (3%) <0.0012 
Chronic lung disease6 
 Yes 
 No 
 Missing 
 
2 (10%) 
19 (90%) 
4  
 
8 (80%) 
2 (20%) 
 
8 (28%) 
21 (72%) 
1  
 
 
<0.0012 
Follow-up      
Number of anesthetic 
procedures first year of life 
2 (2-3) 4 (3-4) 1 (1-2) <0.001 
Weight-for-height z-score at 1 
year 
-0.38 (0.86) -1.80 (0.76) -0.88 (0.97) 0.001 
Height-corrected-for-target 
height z-score at 1 year 
-0.27 (0.96) -0.36 (0.69) -0.43 (0.78) 0.02 
Head circumference-for-age z-
score at 1 year 
-0.47 (1.16) -0.50 (1.31) -0.39 (1.15) 0.96 
Data are expressed as mean (standard deviation), median (interquartile range) or number (percentage), as 
appropriate.   
P-value = significant difference between the groups.  
1 ECMO treatment was given in case of meconium aspiration syndrome (n = 18), persistent pulmonary 
hypertension of the newborn (n = 2), congenital heart disease  (monoventricular heart with transposition of the 
great vessels and total anomalous pulmonary venous return) (n = 1), sepsis (n = 1), respiratory insufficiency 
due to respiratory syncytial virus (n = 1), infant respiratory distress syndrome with bilateral pneumothorax (n = 
1), pulmonary hypoplasia due to bilateral hydrothorax (n = 1). 
2 Fisher’s exact test was used. 
3 PELOD-2 score in the first 24 hours of PICU stay or up to ECMO cannulation if ECMO was initiated in the 
first 24 hours of PICU stay was calculated.16 
4The maximum VIS recorded during PICU stay up until ECMO cannulation for the ECMO-treated patients or 
up until hernia repair for the CDH non-ECMO patients.17 VIS was maximal at the median age of 1 (1-1) day in 
the ECMO patients, at the median age of 1 (0-1) day in the CDH ECMO patients, and at the median age of 0 
(0-1) days in the CDH non-ECMO patients. 
5 Sepsis during initial hospital stay (clinical suspicion of sepsis with positive blood culture). ECMO-other: 2 
patients had sepsis during ECMO; 1 patients after ECMO; maximum VIS during sepsis: 10 (5-15). CDH-
ECMO: 4 patients had sepsis after ECMO; maximum VIS during sepsis: 2.5 (0-32.5). CDH non-ECMO: 1 
patient had sepsis after hernia repair; maximum VIS during sepsis: 0. 
6 Chronic lung disease defined as oxygen dependency at 28 days of life.18 
Abbreviations: CDH = congenital diaphragmatic hernia; CPR = cardiopulmonary resuscitation; ECMO = 
extracorporeal membrane oxygenation; PELOD-2 = Pediatric Logistic Organ Dysfunction-2; PICU=pediatric 
intensive care unit; VA = veno-arterial; VIS = vasoactive-inotropic score; VV = veno-venous. 
 
 1 
 2 
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Table 2. Overview of neuropsychological assessment outcome 
Neuropsychological test All            
(n = 65) 
ECMO-other      
(n = 25)1 
CDH-ECMO      
(n = 10) 
CDH-non-ECMO         
(n = 30) 
p-value  
Intelligence      
 WISC-III-NL  95 (16) 94 (10) 84 (12) 100 (20) .029 
Attention      
 TMT A  -0.33 (0.86) -0.25 (1.05) -0.45 (0.53) -0.36 (0.79) .963 
 TMT B  -0.18 (0.98) 0.08 (1.03) -0.28 (1.08) -0.37 (0.88) .267 
 STROOP -0.61 (1.01) -1.00 (0.76) -0.29 (1.11) -0.39 (1.10) .081 
 DCT -2.73 (2.57) -2.88 (2.09) -3.88 (2.91) -2.25 (2.76) .173 
Verbal memory      
 WISC-III-NL Digit span 0.06 (1.09) -0.08 (1.15) -0.34 (0.94) 0.31 (1.07) .706 
 RAVLT immediate -1.09 (1.27) -1.26 (1.24) -1.55 (1.03) -0.79 (1.33) .664 
 RAVLT delayed -1.14 (1.86) -1.38 (1.46) -1.87 (1.16) -0.70 (2.24) .117 
Visuospatial memory      
 WNV Spatial Span -0.31 (0.99) -0.39 (0.79) -0.85 (0.76) -0.06 (1.14) .613 
 RCFT immediate -1.48 (1.02) -1.52 (1.02) -1.86 (0.69) -1.31 (1.09) .417 
 RCFT delayed -1.57 (1.01) -1.56 (1.01) -1.89 (0.77) -1.47 (1.09) .689 
 RCFT recognition -1.07 (3.10) -1.09 (1.51) -0.62 (0.95) -0.47 (1.22) .117 
Executive functioning      
 Key Search -0.12 (0.94) -0.26 (0.98) -0.04 (1.09) -0.05 (0.89) .694 
 Modified Six Elements -0.60 (0.87) -0.95 (0.90) -0.46 (0.47) -0.46 (0.92) .194 
Visual spatial processing      
 RCFT copy -0.26 (1.02) -0.36 (1.00) -0.69 (1.02) -0.02 (1.01) .107 
Mean (standard deviation)=average IQ score or average z-score of the neuropsychological test.  
One-way analysis of variance was used to identify differences between the groups on neuropsychological outcome.   
P-value=significant difference between the groups.  
1 ECMO treatment was given in case of meconium aspiration syndrome (n = 18), persistent pulmonary 
hypertension of the newborn (n = 2), congenital heart disease  (monoventricular heart with transposition of the 
great vessels and total anomalous pulmonary venous return) (n = 1), sepsis (n = 1), respiratory insufficiency due to 
respiratory syncytial virus (n = 1), infant respiratory distress syndrome with bilateral pneumothorax (n = 1), 
pulmonary hypoplasia due to bilateral hydrothorax (n = 1). 
Abbreviations: CDH = congenital diaphragmatic hernia; DCT = dot cancellation test; ECMO = extracorporeal 
membrane oxygenation; RAVLT = Rey auditory verbal learning test; RCFT = Rey complex figure test; STROOP 
= Stroop color word test; TMT = trail making test; WISC-III-NL = Wechsler Intelligence Scale for Children, 
Dutch version.  
Please refer to supplementary file 1 for a description of the neuropsychological tests. 
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Table 3. Patient characteristics and neuropsychological outcome at eight years of age 
Variables Intelligence Sustained attention  Verbal memory 
immediate 
Verbal memory 
delayed 
Visuosp  
memory  
 
  
Univariable analyses with medical predictors 
CDH-non-ECMO1 B = 9.84,  p = .031 
(CI 0.96 – 18.72) 
B = 1.73,  p = .016 
(CI 0.34 – 3.12) 
B = 0.70,  p = .068 
(CI -0.05 – 1.46) 
B = 0.86,  p = .145 
(CI -0.31 – 2.02) 
B = 0.3      
(CI -0.2    
       
    
CDH-ECMO2 B = -14.11,  p = .016 
(CI -25.48 – -2.74) 
B = -1.84,  p = .060 
(CI -0.08 – 3.76) 
B = -0.73,  p = .144 
(CI -1.73 – 0.26) 
B = -0.97,  p = .204 
(CI -2.48 – 0.54) 
B = -0.4      
(CI -1.1    
       
    
ECMO-other3 B = -1.59,  p = .745 
(CI -11.37 – 8.19) 
B = -0.77,  p = .312 
(CI -2.30 – 0.75) 
B = -0.29,  p = .475 
(CI -1.11 – 0.53) 
B = -0.31,  p = .622 
(CI -1.55 – 0.94) 
B = -0.4      
(CI -0.6    
       
    
VA-ECMO4 B = -12.59,  p = .002 
(CI -19.97 – -5.20) 
B = -0.42,  p = .670 
(CI -2.46 – 1.61) 
B = -0.38,  p = .457 
(CI -1.41 – 0.66) 
B = -0.25,  p = .677 
(CI -1.47 – 0.97) 
B = -0.2      
(CI -0.9    
       
    
Sepsis5 B = -12.36,  p = .064 
(CI -25.46 – 0.74) 
B = -0.86,  p = .451 
(CI -1.42 – 3.15) 
B = -0.52,  p = .363 
(CI -1.65 – 0.62) 
B = -0.93,  p = .281 
(CI -2.63 – 0.78) 
B = -0.2      
(CI -1.0    
       
    
VIS6 B = -0.08,  p = .105 
(CI -0.17 – 0.02) 
B = -0.01,  p = .217 
(CI 0.01 – -0.03) 
B = -0.01,  p = .014 
(CI -0.02 – -0.002) 
B = -0.02,  p = .004 
(CI -0.03 – -0.01) 
B = -0.0      
(CI -0.0    
       
    
Ventilator-free 
days7 
B = 0.70,  p = .006 
(CI 0.22 – 1.19) 
B = 0.07,  p = .098 
(CI 0.16 – -0.01) 
B = 0.04,  p = .035 
(CI 0.00 – 0.09) 
B = 0.08,  p = .025 
(CI 0.01 – 0.14) 
B = 0.0      
(CI 0.0    
       
    
Initial hospital 
stay (days) 
B = -0.16,  p = .004 
(CI -0.27 – -0.06) 
B = -0.01,  p = .133 
(CI 0.00 – -0.03) 
B = -0.01,  p = .045 
(CI -0.02 – 0.000) 
B = -0.01,  p = .133 
(CI -0.03 – 0.004) 
B = -0.0      
(CI -0.0    
       
    
Anesthetics8 B = -2.92,  p = .027 
(CI -5.49 – -0.35) 
B = -0.44,  p = .036 
(CI -0.03 – -0.85) 
B = -0.15,  p = .179 
(CI -0.37 – 0.72) 
B = -0.23,  p = .175 
(CI -0.57 – 0.11) 
B = -0.0      
(CI -0.2    
       
    
Univariable analyses with growth predictors 
Weight-for-height 
z-score at 1 year 
B = 6.41,  p = .002 
(CI 2.48 – 10.33) 
B = 0.42,  p = .275 
(CI -0.35 – 1.19) 
B = 0.35,  p = .053 
(CI -0.01  – 0.69) 
B = 0.29,  p = .323 
(CI -0.30  – 0.89) 
B = 0.23      
(CI -0.0     
       
     
Height-corrected-
for-target height 
z-score at 1 year 
B = 0.54,  p = .835 
(CI -4.70 – 5.79) 
B = 0.21,  p = .639 
(CI 0.68 – 1.10) 
B = 0.28,  p = .203 
(CI -0.16  – 0.71) 
B = 0.38,  p = .287 
(CI -0.33  – 1.09) 
B = -0.0      
(CI -0.3     
       
     
Head 
circumference-
for-age z-score at 
1 year 
 
B = 3.98,  p = .060 
(CI -0.18 – 8.13) 
B = 0.27,  p = .413 
(CI -0.39 – 0.94) 
B = 0.21,  p = .237 
(CI -0.14  – 0.55) 
B = 0.23,  p = .445 
(CI -0.37  – 0.83) 
B = 0.13      
(CI -0.1     
       
     
Multivariable analyses 
VIS    B = -0.02,  p = .026 
(CI -0.03 – -0.002) 
        
    
Maternal education level, ethnicity and gender were adjusted for in all models. Growth parameters were z-scores. Variable      
predictors in the univariable analyses were added into the multivariable model. Only those variables found to be significant      
reported. Results indicate significant associations at p-value < .05.  
1 CDH -non-ECMO patients were compared to patients treated with ECMO.  
2 CDH-ECMO patients were compared to patients treated with ECMO following other diagnoses and to CDH patients not t     
3 ECMO patients following other diagnosis  were compared to CDH patients treated with and without ECMO. 
4 Patients treated with VA-ECMO were compared to patients treated with VV-ECMO.  
5 Sepsis during initial hospital stay (clinical suspicion of sepsis with positive blood culture). 
6 The maximum VIS recorded during pediatric intensive care unit stay up until ECMO cannulation for the ECMO-treated p       
for the CDH-non-ECMO patients.  
7 Ventilator-free days in the first 28 days of life.  
8 Number of anesthetic procedures in the first year of life. 
Abbreviations: CDH = congenital diaphragmatic hernia; ECMO = extracorporeal membrane oxygenation; VIS = vasoactiv      
confidence interval; VA-ECMO = venoarterial extracorporeal membrane oxygenation; VV-ECMO = venovenous extracorp     
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Figures 1 
 2 
Figure 1 Presence of neuropsychological impairments in the study population 3 
Percentage of patients with a z-score ≤ -1 (impaired; as shown by the dark colored bars) and > -1 (normal; 4 
as shown by the grey colored bars) on each of the neuropsychological tests.   5 
Abbreviations: WISC-III-NL = Wechsler Intelligence Scale for Children, Dutch version; TMT = Trail 6 
Making Test; Stroop = Stroop Color Word Test; DCT = Dot Cancellation Test; RAVLT = Rey Auditory 7 
Verbal Learning Test; RCFT = Rey Complex Figure Test.  8 
Please refer to the Supplemental File for a description of the tests. 9 
 10 
 11 
 12 
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Supplementary Material 1 
 2 
Supplemental Figure 1 Flowchart of the study population 3 
*ECMO-other group: n = 12; ECMO-CDH-group: n = 10; CDH-non-ECMO group: n =  6. 4 
† Severe neurologic or developmental impairments (n = 5; 3 patients had primary hemorrhage at cranial 5 
ultrasound performed after the ECMO run); Simpson-Golabi-Behmel Syndrome (n = 2); Down Syndrome 6 
(n = 1); Mitochondriopathy (n = 1). 7 
Abbreviations: CDH = congenital diaphragmatic hernia; ECMO = extracorporeal membrane oxygenation. 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
25 
 
Supplemental methods Description of data collection 1 
Relevant clinical data were collected at the time of hospitalization (refer to supplementary methods for 2 
description of variables). , including: gestational age, birth weight, gender, ethnicity (Dutch/≥1 non-native 3 
Dutch parent), inborn, the need for ECMO, Pediatric Logistic Organ Dysfunction-2(PELOD-2) score(16) 4 
in the first 24 hours of pediatric intensive care unit(PICU) stay (or up to ECMO cannulation in ECMO-5 
treated patients if ECMO was initiated in the first 24 hours of PICU stay), the maximum vasoactive-6 
inotropic score (VIS)(17) was recorded up until ECMO cannulation for the ECMO-treated patients or up 7 
until hernia repair for the CDH-non-ECMO patients, cardiopulmonary resuscitation(CPR) during initial 8 
hospital stay, sepsis during initial hospital stay (clinical suspicion of sepsis with positive blood culture), 9 
duration of initial mechanical ventilation, ventilator-free days in the first 28 days of life, duration of PICU 10 
stay, duration of initial hospitalization, pulmonary hypertension on echocardiography during PICU 11 
admission, inhaled nitric oxide requirement, sildenafil requirement, the presence of chronic lung 12 
disease(oxygen dependency at 28 days of life)(18), and number of anesthetic procedures in the first year 13 
of life (including CDH repair and/or ECMO (de)cannulation). Additional characteristics for ECMO 14 
patients included: highest oxygenation index before ECMO, age at start ECMO, ECMO type, ECMO 15 
duration, and cranial ultrasound result before and after ECMO. Additional data for CDH patients were: 16 
diaphragmatic defect side, surgical repair technique (thoracoscopy or laparotomy), age at surgery, and 17 
patch repair requirement. 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
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Supplemental Table 1 Patient characteristics and neuropsychological outcome at eight years of age 1 
Supplemental Table 1. Patient characteristics and neuropsychological outcome at eight years of age 
Variables Intelligence Sustained attention  Verbal memory 
immediate 
Verbal memory 
delayed 
Visuospat   
immediate 
  
 
Univariable analyses with medical predictors 
CDH-non-ECMO1 B = 9.84,  p = .031 
(CI 0.96 – 18.72) 
B = 1.73,  p = .016 
(CI 0.34 – 3.12) 
B = 0.70,  p = .068 
(CI -0.05 – 1.46) 
B = 0.86,  p = .145 
(CI -0.31 – 2.02) 
B = 0.31,     
(CI -0.23   
       
    
CDH-ECMO2 B = -14.11,  p = .016 
(CI -25.48 – -2.74) 
B = -1.84,  p = .060 
(CI -0.08 – 3.76) 
B = -0.73,  p = .144 
(CI -1.73 – 0.26) 
B = -0.97,  p = .204 
(CI -2.48 – 0.54) 
B = -0.45      
(CI -1.16   
       
    
ECMO-other3 B = -1.59,  p = .745 
(CI -11.37 – 8.19) 
B = -0.77,  p = .312 
(CI -2.30 – 0.75) 
B = -0.29,  p = .475 
(CI -1.11 – 0.53) 
B = -0.31,  p = .622 
(CI -1.55 – 0.94) 
B = -0.48,     
(CI -0.63   
       
    
VA-ECMO4 B = -12.59,  p = .002 
(CI -19.97 – -5.20) 
B = -0.42,  p = .670 
(CI -2.46 – 1.61) 
B = -0.38,  p = .457 
(CI -1.41 – 0.66) 
B = -0.25,  p = .677 
(CI -1.47 – 0.97) 
B = -0.23,     
(CI -0.97   
       
    
Sepsis5 B = -12.36,  p = .064 
(CI -25.46 – 0.74) 
B = -0.86,  p = .451 
(CI -1.42 – 3.15) 
B = -0.52,  p = .363 
(CI -1.65 – 0.62) 
B = -0.93,  p = .281 
(CI -2.63 – 0.78) 
B = -0.23,     
(CI -1.04   
       
    
VIS6 B = -0.08,  p = .105 
(CI -0.17 – 0.02) 
B = -0.01,  p = .217 
(CI 0.01 – -0.03) 
B = -0.01,  p = .014 
(CI -0.02 – -0.002) 
B = -0.02,  p = .004 
(CI -0.03 – -0.01) 
B = -0.01      
(CI -0.01   
       
    
Ventilator-free 
days7 
B = 0.70,  p = .006 
(CI 0.22 – 1.19) 
B = 0.07,  p = .098 
(CI 0.16 – -0.01) 
B = 0.04,  p = .035 
(CI 0.00 – 0.09) 
B = 0.08,  p = .025 
(CI 0.01 – 0.14) 
B = 0.03,     
(CI 0.00 –  
       
    
Initial hospital stay 
(days) 
B = -0.16,  p = .004 
(CI -0.27 – -0.06) 
B = -0.01,  p = .133 
(CI 0.00 – -0.03) 
B = -0.01,  p = .045 
(CI -0.02 – 0.000) 
B = -0.01,  p = .133 
(CI -0.03 – 0.004) 
B = -0.00,     
(CI -0.01   
       
    
Anesthetics8 B = -2.92,  p = .027 
(CI -5.49 – -0.35) 
B = -0.44,  p = .036 
(CI -0.03 – -0.85) 
B = -0.15,  p = .179 
(CI -0.37 – 0.72) 
B = -0.23,  p = .175 
(CI -0.57 – 0.11) 
B = -0.04,     
(CI -0.20   
       
    
Univariable analyses with growth predictors 
Weight-for-height 
z-score at 1 year 
B = 6.41,  p = .002 
(CI 2.48 – 10.33) 
B = 0.42,  p = .275 
(CI -0.35 – 1.19) 
B = 0.35,  p = .053 
(CI -0.01  – 0.69) 
B = 0.29,  p = .323 
(CI -0.30  – 0.89) 
B = 0.23,     
(CI -0.03    
       
     
Height-corrected-
for-target height z-
score at 1 year 
B = 0.54,  p = .835 
(CI -4.70 – 5.79) 
B = 0.21,  p = .639 
(CI 0.68 – 1.10) 
B = 0.28,  p = .203 
(CI -0.16  – 0.71) 
B = 0.38,  p = .287 
(CI -0.33  – 1.09) 
B = -0.01,     
(CI -0.34    
       
     
Head 
circumference-for-
age z-score at 1 
year 
B = 3.98,  p = .060 
(CI -0.18 – 8.13) 
B = 0.27,  p = .413 
(CI -0.39 – 0.94) 
B = 0.21,  p = .237 
(CI -0.14  – 0.55) 
B = 0.23,  p = .445 
(CI -0.37  – 0.83) 
B = 0.13,     
(CI -0.14    
       
     
Multivariable analyses 
CDH-non-ECMO1 B = 7.33,  p = .213 
(CI -4.42 – 19.07) 
B = 1.29,  p = .110 
(CI -2.90 – 0.31) 
    
CDH-ECMO2 B = -1.66,  p = .851 
(CI -19.51 – 16.18) 
     
VA-ECMO3 B = -8.03,  p = .131 
(CI -18.83 – 2.76) 
     
VIS6   B = -0.01,  p = .055 
(CI -0.02 – -0.000) 
B = -0.02,  p = .026 
(CI -0.03 – -0.002) 
B = -0.01,     
(CI -0.01   
       
    
Ventilator-free 
days7 
B = -0.28,  p = .571 
(CI -1.29 – 0.72) 
 B = 0.02,  p = .580 
(CI -0.06 – 0.10) 
B = 0.02,  p = .555 
(CI -0.06 – 0.10) 
B = 0.01,     
(CI -0.03   
       
    
Initial hospital stay 
(days) 
B = -0.14,  p = .225 
(CI -0.36 – 0.09) 
 B = 0.00,  p = .784 
(CI -0.01 – 0.02) 
   
Anesthetics8 B = 0.40,  p = .831 
(CI -3.36 – 4.15) 
B = 0.25,  p = .285 
(CI -0.22 – 0.72) 
    
Weight-for-height 
z-score at 1 year 
B = 3.85,  p = .180 
(CI -1.88 – 9.58) 
     
Maternal education level, ethnicity and gender were adjusted for in all models. Growth parameters were z-scores. Variable      
predictors in the univariable analyses were added into the multivariable model. Only those variables found to be significant      
reported. Results indicate significant associations at p-value < .05.  
1 CDH -non-ECMO patients were compared to patients treated with ECMO.  
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2 CDH-ECMO patients were compared to patients treated with ECMO following other diagnoses and to CDH patients not t     
3 ECMO patients following other diagnosis  were compared to CDH patients treated with and without ECMO. 
4 Patients treated with VA-ECMO were compared to patients treated with VV-ECMO.  
5 Sepsis during initial hospital stay (clinical suspicion of sepsis with positive blood culture). 
6 The maximum VIS recorded during pediatric intensive care unit stay up until ECMO cannulation for the ECMO-treated p       
for the CDH-non-ECMO patients.  
7 Ventilator-free days in the first 28 days of life.  
8 Number of anesthetic procedures in the first year of life. 
Abbreviations: CDH = congenital diaphragmatic hernia; ECMO = extracorporeal membrane oxygenation; VIS = vasoactiv      
confidence interval; VA-ECMO = venoarterial extracorporeal membrane oxygenation; VV-ECMO = venovenous extracorp     
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Supplemental File 1. Descriptions of the neurodevelopmental tests. 1 
Intelligence  2 
Wechsler Intelligence Scale for Children (WISC-III-NL) 3 
The RAKIT or the Wechsler Intelligence Scale for children was used. Both tests assess verbal and non-4 
verbal intelligence, have been shown to have good reliability and validity(1, 2), and have been used 5 
interchangeably by our group before.(3) For both tests, a normalized population mean of 100 with a 6 
standard deviation of 15 is used.(1, 2) 7 
 8 
Attention  9 
Dot Cancellation Test 10 
This paper-and-pencil test measures sustained selective attention and concentration in terms of 11 
speed and accuracy. It consists of a paper on which figures made of three, four or five dots are 12 
displayed in 33 rows. The child is instructed to cross off all figures with four dots, as precise and 13 
as fast as they can.(4)  14 
 15 
Stroop Color Word Test (Stroop) 16 
The Stroop consists of three trials: in the first trial (Stroop 1) the subject must read color names, 17 
in the second trial (Stroop 2) name printed colors, and in the third trial (Stroop 3) name printed 18 
colors not denoted by the color name. The test can be administered to children and adults in the 19 
age range 8-65 years. Selective attention is measured with this test.(5, 6)  20 
 21 
Trail Making Test (TMT) 22 
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This paper and pencil test consists of two parts. In the first part (part A), the subject must draw 1 
lines to consecutively connect numbered circles on a sheet. In the second part (part B), the 2 
subject must consecutively but alternately connect numbered and lettered circles on another 3 
worksheet. The goal of the test is to finish each part as quickly as possible.  The test can be 4 
administered to children and adults in the age range 6-89 years. This test measures visual 5 
conceptual and visuomotor tracking as well as divided attention.(5, 6) 6 
 7 
Verbal memory  8 
WISC-III-NL – subtest Digit Span  9 
The Digit Span consists of random number sequences that increase in length and that the 10 
examiner reads aloud at the rate of 1 number per second. The child has to reproduce these 11 
numbers in the same order. Next, the sequences must be recalled backwards (3-5-7 becomes 7-5-12 
3). The first part of the test measures short-term auditory memory and short-term retention 13 
capacity. The second part measures auditory working memory. A difference of 4 or more points 14 
between forward and backward Digit Span in favor of forward is indicative of a working-15 
memory problem.(7)  16 
 17 
Rey Auditory Verbal Learning Test (RAVLT) 18 
The RAVLT consists of five presentations with recall of a 15-word list, a sixth recall trial after 19 
30 minutes, and a seventh recognition trial. This test measures memory span, short- and long-20 
term verbal memory, verbal recognition, learning curve, and retroactive or proactive 21 
interference. It can be administered to children and adults in the age range 6-89 years.(8, 9) 22 
 23 
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Visuospatial memory  1 
Wechsler Nonverbal Scale of Ability (WNV) – subtest Spatial Span  2 
The Spatial Span requires the child to touch a group of block arranged on a board in a 3 
nonsystematic manner in the same and reverse order as demonstrated by the examiner. The first 4 
part of the test measures short-term visuospatial memory and short-term retention capacity. The 5 
second part measures visuospatial working-memory.(10)  6 
 7 
Rey Complex Figure Test (RCFT) 8 
The RCFT consist of three trials. First the child has to copy a complex figure. Then after 3 and 9 
after 30 minutes the figure must be drawn from memory. Next, different figures are shown and 10 
the child has to indicate whether these figures were in the original figure. The last two trials 11 
measure short- and long-term visual-spatial memory, and visual-spatial recognition. This test can 12 
be completed by children and adults in the age range 6-89 years.(11, 12)  13 
 14 
Executive functioning  15 
Key Search  16 
A test of strategy formation. The child is asked to demonstrate how they would search a field for 17 
a set of lost keys and their strategy is scored according to its functionality.(13)  18 
 19 
Modified Six Elements 20 
The child is asked to work on six different tasks for which they have five minutes. There are 21 
some rules the child has to obey during the task, while making sure that by the end of the five 22 
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minutes, all six of the tasks have been done and the child has done as much as possible of each 1 
task. This is a test of planning, task scheduling and performance monitoring.(13)  2 
 3 
Visual spatial processing  4 
Rey Complex Figure Test (RCFT) 5 
The RCFT consists of three trials. First the child has to copy a complex figure. Then after 3 and 6 
after 30 minutes the figure must be drawn from memory. Next, different figures are shown and 7 
the child has to indicate whether these figures were in the original figure. The first trial measures 8 
visual integration. This test can be completed by children and adults in the age range 6-89 9 
years.(11, 12)  10 
 11 
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